Cyp1a1 (ile462val), CYP1B1 (ala119ser and val432leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a turkish population

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3925-3929

  Berber, Ufuk ^a   Yilmaz, Ismail ^a   Yilmaz, Omer ^a   Haholu, Aptullah ^a   Kucukodaci, Zafer ^a   Ates, Ferhat ^a   Demirel, Dilaver ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Bladder cancer; CYP1A1; CYP1B1; GSTM1; GSTT1

Indexed keywords

CYP1A1 PROTEIN, HUMAN; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; UNSPECIFIC MONOOXYGENASE; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADULT; AGED; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTOR; TURKEY; URINARY BLADDER NEOPLASMS; VERY ELDERLY; ARTICLE; BLADDER TUMOR; TURKEY (REPUBLIC);

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1B1; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TURKEY; URINARY BLADDER NEOPLASMS;

EID: 84882587391     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3925     Document Type: Article

References (28)

1. Aktas D, Guney I, Alikasifoglu M, et al (2002). CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol, 86, 124-8.
2. Aktas D, Hascicek M, Sozen S, et al (2004). CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Gene Cytogenet, 154, 81-5.
3. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y (2009). CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol, 41, 259-66.
4. Atinkaya C, Taspinar M, Sakiragaoglu S, et al (2012). The effect of CYP1A1, GSTT1 and GSTM1 polymorphisms on the risk of lung cancer: a case-control study. Hum Exp Toxicol, 31, 1074-80.
5. Bartsch H, Nair U, Risch A, et al (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev, 9, 3-28.
6. Boffetta P, Jourenkova N, Gustavsson P (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control, 8, 444-72.
7. Botelho MC, Machado JC, da Costa JMC (2010). Schistosoma haematobium and bladder cancer. What lies beneath? Virulence, 1, 84-7.
8. Cengiz M, Ozaydin A, Ozkilic AC, Dedekarginoglu G (2007). The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients. Int Urol Nephrol, 39, 1043-8.
9. Dong LM, Potter JD, White E, et al (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-36.
10. Fatima M, Garća N, Munoz X, et al (2010). Simultaneous genotyping of GSTT1 and GSTM1 null polymorphisms by melting curve analysis in presence of SYBR Green I. J Mol Diagn, 12, 300-4.
11. Feng Z, Hu W, Rom WN, Beland FA, Tang MS (2002). 4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis, 23, 1721-7.
12. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res, 60, 3440-4.
13. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H (1992). Point-mutational MspI and Ile±Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev, 1, 485-9.
14. Ji YN, Wang Q, Suo LJ (2012). CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: A meta-analysis. PLoS ONE, 7, 43397.
15. Lee KM, Kang D, Clapper ML, et al (2008). CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among asian populations. Cancer Epidemiol Biomarkers Prev, 17, 1120-6.
16. Lopez-beltran A, Cheng L, Mazzucchelli R, et al (2008). Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Res, 28, 2893-900.
17. Pollard C, Smith SC, Theodorescu D (2010). Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med, 12, 10.
18. Rebbeck TR, Walker AH, Jaffe JM, et al (1999). Glutathione S-transferase-μ (GSTM1) and -? (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev, 8, 283-7.
19. Salinas-Sanchez AS, Donate-Moreno MJ, López-Garrido MP, Giménez-Bachs JM, Escribano J (2012). Role of CYP1B1 gene polymorphisms in bladder cancer cusceptibility. J Urol, 187, 700-6.
20. Senthilkumar KP, Thirumurugan R (2012). GSTM1 and GSTT1 allele frequencies among various Indian and non-Indian ethnic groups. Asian Pac J Cancer Prev, 13, 6263-7.
21. Sharma A, Pandey A, Sardana S, et al (2012). Genetic polymorphisms of GSTM1 and GSTT1 genes in Delhi and comparison with other Indian and global populations. Asian Pac J Cancer Prev, 13, 5647-52.
22. Shukla D, Dinesh KA, Hallikerimath S, Vivekanandhan S, Venkatakanthaiah Y (2012). Genetic polymorphism of drug metabolizing enzymes (GSTM1 and CYP1A1) as risk factors for oral premalignant lesions and oral cancer. Biomedical Papers, 156, 253-9.
23. Song DK, Xing DL, Zhang LR, et al (2009). Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in central China. Cancer Detection and Prev, 32, 416-23.
24. Tanaka Y, Sasaki M, Kaneuchi M, et al (2002). Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun, 296, 820-6.
25. Toruner GA, Akyerli C, Ucar A, et al (2001). Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in Turkish population. Arch Toxicol, 75, 459-64.
26. Turesky RJ, Le Marchand L (2011). Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. Chem Res Toxicol, 24, 1169-214.
27. Yang CX, Matsuo K, Wang ZM, Tajima K (2005). Phase I/II enzyme gene polymorphisms and esophageal cancer risk: A meta-analysis of the literature. World J Gastroenterol, 11, 2531-8.
28. Zhou LP, Luan H, Dong XH, et al (2012). Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 3165-72.